$ELTP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ELITE PHARMACEUTICALS INC /NV/.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ELITE PHARMACEUTICALS INC /NV/. Get notifications about new insider transactions in ELITE PHARMACEUTICALS INC /NV/ for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 26 2020 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Option Exercise | C | 0.00 | 24 | 0 | 0 | |
Aug 26 2020 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Buy | C | 0.00 | 158,017,321 | 0 | 167,114,882 | 9.1 M to 167.1 M (+1,736.92 %) |
Aug 24 2020 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | SVP Operations | Grant | A | 0.09 | 71,739 | 6,284 | 1,133,932 | 1.1 M to 1.1 M (+6.75 %) |
Aug 24 2020 | ELTP | ELITE PHARMACEUTIC ... | Caskey Davis S | Director | Grant | A | 0.09 | 516,781 | 45,012 | 746,673 | 229.9 K to 746.7 K (+224.79 %) |
Aug 24 2020 | ELTP | ELITE PHARMACEUTIC ... | WHITNELL JEFFREY A | Director | Grant | A | 0.09 | 516,781 | 45,012 | 1,884,257 | 1.4 M to 1.9 M (+37.79 %) |
Aug 24 2020 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Grant | A | 0.09 | 516,781 | 45,012 | 1,932,612 | 1.4 M to 1.9 M (+36.50 %) |
Jul 06 2020 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | SVP of Operations | Grant | A | 0.09 | 574,597 | 49,990 | 1,062,193 | 487.6 K to 1.1 M (+117.84 %) |
Feb 27 2018 | ELTP | ELITE PHARMACEUTIC ... | Pfeifer Eugene M | Director | Grant | A | 0.12 | 161,374 | 19,994 | 233,414 | 72 K to 233.4 K (+224.01 %) |
Feb 27 2018 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | SVP of Operations | Grant | A | 0.12 | 201,717 | 24,993 | 487,596 | 285.9 K to 487.6 K (+70.56 %) |
Feb 27 2018 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | CFO, Sec., Treas. | Grant | A | 0.12 | 242,060 | 29,991 | 2,127,364 | 1.9 M to 2.1 M (+12.84 %) |
Feb 27 2018 | ELTP | ELITE PHARMACEUTIC ... | WHITNELL JEFFREY A | Director | Grant | A | 0.12 | 161,374 | 19,994 | 1,367,476 | 1.2 M to 1.4 M (+13.38 %) |
Feb 27 2018 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Grant | A | 0.12 | 161,374 | 19,994 | 1,415,831 | 1.3 M to 1.4 M (+12.86 %) |
Feb 27 2018 | ELTP | ELITE PHARMACEUTIC ... | Caskey Davis S | Director | Grant | A | 0.12 | 161,374 | 19,994 | 229,892 | 68.5 K to 229.9 K (+235.52 %) |
May 03 2017 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Option Exercise | J | 0.15 | 79,008,661 | 12,017,217 | 79,008,661 | |
May 03 2017 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Option Exercise | J | 1,000,000.00 | 24 | 24,000,000 | 24 | |
May 03 2017 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Sell | J | 0.00 | 158,017,321 | 0 | 9,097,561 | 167.1 M to 9.1 M (-94.56 %) |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | Pfeifer Eugene M | Director | Grant | A | 0.20 | 72,040 | 14,588 | 72,040 | 0 to 72 K |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | Caskey Davis S | Director | Grant | A | 0.20 | 68,518 | 13,443 | 68,518 | 0 to 68.5 K |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | SVP of Operations | Grant | A | 0.23 | 110,849 | 24,996 | 285,879 | 175 K to 285.9 K (+63.33 %) |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | Director | Grant | A | 0.23 | 133,019 | 29,996 | 1,885,304 | 1.8 M to 1.9 M (+7.59 %) |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | WHITNELL JEFFREY A | Director | Grant | A | 0.23 | 88,679 | 19,997 | 1,206,102 | 1.1 M to 1.2 M (+7.94 %) |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Grant | A | 0.23 | 88,679 | 19,997 | 1,254,457 | 1.2 M to 1.3 M (+7.61 %) |
Feb 27 2017 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Grant | A | 0.23 | 2,216,992 | 499,932 | 24,143,785 | 21.9 M to 24.1 M (+10.11 %) |
Aug 19 2016 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Option Exercise | M | 0.00 | 100 | 0 | 0 | |
Aug 19 2016 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Buy | M | 0.00 | 142,857,143 | 0 | 142,971,097 | 114 K to 143 M (+125,363.87 %) |
May 03 2016 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | CFO, Secretary, Tre ... | Option Exercise | C | 0.06 | 666,667 | 41,667 | 0 | |
May 03 2016 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | CFO, Secretary, Tre ... | Buy | C | 0.06 | 666,667 | 41,667 | 1,752,285 | 1.1 M to 1.8 M (+61.41 %) |
Mar 21 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.34 | 258,090 | 88,267 | 7,640,561 | 7.9 M to 7.6 M (-3.27 %) | |
Mar 21 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.35 | 312,430 | 107,788 | 7,898,651 | 8.2 M to 7.9 M (-3.80 %) | |
Feb 24 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.31 | 100,456 | 31,141 | 8,211,081 | 8.3 M to 8.2 M (-1.21 %) | |
Feb 24 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.32 | 100,000 | 32,090 | 8,311,537 | 8.4 M to 8.3 M (-1.19 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.31 | 50,000 | 15,580 | 8,411,537 | 8.5 M to 8.4 M (-0.59 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Grant | A | 0.25 | 124,646 | 30,900 | 8,461,537 | 8.3 M to 8.5 M (+1.50 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.33 | 24,400 | 8,052 | 8,336,891 | 8.4 M to 8.3 M (-0.29 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.32 | 349,660 | 111,891 | 8,361,291 | 8.7 M to 8.4 M (-4.01 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.33 | 45,518 | 15,021 | 8,710,951 | 8.8 M to 8.7 M (-0.52 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.33 | 13,000 | 4,290 | 8,756,469 | 8.8 M to 8.8 M (-0.15 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.34 | 312,300 | 106,182 | 8,769,469 | 9.1 M to 8.8 M (-3.44 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Sell | S | 0.35 | 115,000 | 40,250 | 9,081,769 | 9.2 M to 9.1 M (-1.25 %) | |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | Exec Vice Pres Oper ... | Grant | A | 0.26 | 47,767 | 12,501 | 175,030 | 127.3 K to 175 K (+37.53 %) |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | Chairman, CEO, Pres ... | Grant | A | 0.25 | 2,854,279 | 699,869 | 22,040,747 | 19.2 M to 22 M (+14.88 %) |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | WHITNELL JEFFREY A | Director | Grant | A | 0.25 | 81,549 | 20,004 | 1,117,423 | 1 M to 1.1 M (+7.87 %) |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | CFO, Sec., Treas | Grant | A | 0.25 | 122,325 | 29,994 | 1,085,618 | 963.3 K to 1.1 M (+12.70 %) |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Grant | A | 0.25 | 81,549 | 20,004 | 12,742,395 | 12.7 M to 12.7 M (+0.64 %) |
Feb 18 2016 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Grant | A | 0.25 | 81,549 | 20,004 | 1,165,778 | 1.1 M to 1.2 M (+7.52 %) |
Apr 15 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Option Exercise | C | 0.06 | 1,242,334 | 77,646 | 2,935,986 | ||
Apr 15 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Option Exercise | C | 0.06 | 2,424,333 | 151,521 | 0 | ||
Apr 15 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Option Exercise | C | 0.06 | 333,333 | 20,833 | 0 | ||
Apr 15 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Buy | C | 0.06 | 4,000,000 | 250,000 | 16,742,395 | 12.7 M to 16.7 M (+31.39 %) | |
Jan 08 2016 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Buy | J | 0.00 | 113,954 | 0 | 113,954 | 0 to 114 K |
Jan 08 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | G | 0.06 | 6,000,000 | 375,000 | 3,910,532 | |
Jan 08 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Gift | G | 0.00 | 6,000,000 | 0 | 12,262,006 | 18.3 M to 12.3 M (-32.86 %) |
Jan 08 2016 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Buy | J | 0.00 | 398,840 | 0 | 398,840 | 0 to 398.8 K |
Nov 18 2015 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of Board | Sell | S | 0.31 | 25,000 | 7,625 | 9,196,769 | 9.2 M to 9.2 M (-0.27 %) |
Nov 18 2015 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of Board | Sell | S | 0.30 | 25,000 | 7,503 | 9,221,769 | 9.2 M to 9.2 M (-0.27 %) |
Nov 18 2015 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of Board | Sell | S | 0.30 | 50,000 | 15,125 | 9,246,769 | 9.3 M to 9.2 M (-0.54 %) |
Nov 18 2015 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of Board | Sell | S | 0.30 | 50,000 | 15,000 | 9,296,769 | 9.3 M to 9.3 M (-0.53 %) |
Nov 18 2015 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of Board | Gift | G | 0.31 | 7,500 | 2,325 | 9,346,769 | 9.4 M to 9.3 M (-0.08 %) |
Oct 20 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | G | 0.06 | 5,697,710 | 356,107 | 0 | |
Oct 20 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | G | 0.06 | 1,324,333 | 82,771 | 0 | |
Oct 20 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | G | 0.06 | 2,684,137 | 167,759 | 0 | |
Oct 20 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | G | 0.06 | 454,665 | 28,417 | 0 | |
Aug 18 2015 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | 10% Owner | Grant | A | 0.23 | 54,169 | 12,502 | 127,263 | 73.1 K to 127.3 K (+74.11 %) |
Jun 22 2015 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | Senior VP of Operat ... | Option Exercise | A | 0.07 | 3,000,000 | 210,000 | 3,000,000 | |
Jun 04 2015 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Option Exercise | C | 0.06 | 1,982,106 | 123,882 | 0 | |
Jun 04 2015 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Option Exercise | C | 0.06 | 759,695 | 47,481 | 0 | |
Jun 04 2015 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Buy | C | 0.06 | 2,741,801 | 171,363 | 5,311,819 | 2.6 M to 5.3 M (+106.68 %) |
May 21 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | C | 0.06 | 2,000,000 | 125,000 | 2,000,000 | |
May 21 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Buy | C | 0.06 | 2,000,000 | 125,000 | 40,442,232 | 38.4 M to 40.4 M (+5.20 %) |
May 13 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | C | 0.06 | 2,000,000 | 125,000 | 454,665 | |
May 13 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | G | 0.06 | 350,000 | 21,875 | 1,324,333 | |
May 13 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Buy | C | 0.06 | 2,000,000 | 125,000 | 38,442,232 | 36.4 M to 38.4 M (+5.49 %) |
Apr 28 2015 | ELTP | ELITE PHARMACEUTIC ... | Plassche Douglas | Executive VP of Ope ... | Sell | S | 0.24 | 85,530 | 20,168 | 73,094 | 158.6 K to 73.1 K (-53.92 %) |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Buy | J | 0.00 | 2,570,018 | 0 | 2,570,018 | 0 to 2.6 M |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Buy | J | 0.00 | 12,850,089 | 0 | 31,269,108 | 18.4 M to 31.3 M (+69.77 %) |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | J | 0.00 | 67,659,232 | 0 | 0 | 67.7 M to 0 (-100.00 %) |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Buy | J | 0.00 | 19,275,133 | 0 | 55,717,363 | 36.4 M to 55.7 M (+52.89 %) |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Sell | J | 0.00 | 67,659,232 | 0 | 0 | 67.7 M to 0 (-100.00 %) |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Sell | J | 0.00 | 67,659,232 | 0 | 0 | 67.7 M to 0 (-100.00 %) |
Apr 27 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Sell | J | 0.00 | 67,659,232 | 0 | 0 | 67.7 M to 0 (-100.00 %) |
Apr 16 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | G | 0.06 | 1,250,000 | 78,125 | 1,204,665 | |
Apr 08 2015 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Option Exercise | J | 0.06 | 1,982,106 | 123,882 | 1,982,106 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 4,000,000 | 250,000 | 4,000,000 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 2,684,137 | 167,759 | 2,684,137 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 6,726,999 | 420,437 | 15,349,042 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 2,454,665 | 153,417 | 2,454,665 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 4,000,000 | 250,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 40,000,000 | 2,500,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 6,726,999 | 420,437 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Option Exercise | J | 0.06 | 2,454,665 | 153,417 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 9,910,532 | 619,408 | 9,910,532 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 4,000,000 | 250,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 40,000,000 | 2,500,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 6,726,999 | 420,437 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 2,454,665 | 153,417 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Option Exercise | J | 0.06 | 4,000,000 | 250,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Option Exercise | J | 0.06 | 40,000,000 | 2,500,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Option Exercise | J | 0.06 | 6,726,999 | 420,437 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Option Exercise | J | 0.06 | 2,454,665 | 153,417 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Option Exercise | J | 0.06 | 4,000,000 | 250,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Option Exercise | J | 0.06 | 40,000,000 | 2,500,000 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Option Exercise | J | 0.06 | 6,726,999 | 420,437 | 0 | |
Apr 07 2015 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Option Exercise | J | 0.06 | 2,454,665 | 153,417 | 0 | |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Director | Grant | A | 0.34 | 58,475 | 19,998 | 17,167,097 | 17.1 M to 17.2 M (+0.34 %) |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Grant | A | 0.34 | 58,475 | 19,998 | 5,568,930 | 5.5 M to 5.6 M (+1.06 %) |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | WHITNELL JEFFREY A | Director | Grant | A | 0.34 | 58,475 | 19,998 | 1,035,874 | 977.4 K to 1 M (+5.98 %) |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Grant | A | 0.34 | 58,475 | 19,998 | 1,084,229 | 1 M to 1.1 M (+5.70 %) |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of Board | Grant | A | 0.34 | 87,711 | 29,997 | 9,354,269 | 9.3 M to 9.4 M (+0.95 %) |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | CFO, Secretary, Tre ... | Grant | A | 0.34 | 87,711 | 29,997 | 963,293 | 875.6 K to 963.3 K (+10.02 %) |
Mar 09 2015 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | President & CEO | Grant | A | 0.34 | 2,046,554 | 699,921 | 13,760,695 | 11.7 M to 13.8 M (+17.47 %) |
Jan 08 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Option Exercise | C | 0.06 | 1,500,000 | 93,750 | 8,622,043 | |
Jan 08 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Option Exercise | C | 0.06 | 1,333,333 | 83,333 | 0 | |
Jan 08 2015 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Buy | C | 0.06 | 2,833,333 | 177,083 | 17,108,622 | 14.3 M to 17.1 M (+19.85 %) |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Option Exercise | J | 0.06 | 759,695 | 47,481 | 759,695 | |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 4,178,320 | 261,145 | 8,602,653 | |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | J | 0.06 | 20,000,002 | 1,250,000 | 6,726,999 | |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Option Exercise | J | 0.06 | 5,697,710 | 356,107 | 10,122,043 | |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Option Exercise | J | 0.06 | 20,000,002 | 1,250,000 | 6,726,999 | |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Option Exercise | J | 0.06 | 20,000,002 | 1,250,000 | 6,726,999 | |
Oct 21 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Option Exercise | J | 0.06 | 20,000,002 | 1,250,000 | 6,726,999 | |
Sep 29 2014 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Buy | P | 0.31 | 265,500 | 82,385 | 2,700,000 | 2.4 M to 2.7 M (+10.91 %) |
Sep 29 2014 | ELTP | ELITE PHARMACEUTIC ... | Hakim Nasrat A | CEO & President | Buy | P | 0.31 | 434,500 | 133,956 | 2,434,500 | 2 M to 2.4 M (+21.73 %) |
Sep 12 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Option Exercise | C | 0.07 | 4 | 0 | 0 | |
Sep 12 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Buy | C | 0.00 | 6,060,000 | 0 | 9,266,558 | 3.2 M to 9.3 M (+188.99 %) |
Aug 12 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Option Exercise | G | 0.06 | 2,000,000 | 125,000 | 2,757,666 | |
Jun 23 2014 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Option Exercise | C | 0.25 | 12,423 | 3,106 | 0 | |
Jun 23 2014 | ELTP | ELITE PHARMACEUTIC ... | Dash Barry H | Director | Buy | C | 0.25 | 12,423 | 3,106 | 1,025,754 | 1 M to 1 M (+1.23 %) |
Jun 18 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Option Exercise | C | 0.25 | 375,000 | 93,750 | 0 | |
Jun 18 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Buy | C | 0.25 | 375,000 | 93,750 | 3,206,558 | 2.8 M to 3.2 M (+13.24 %) |
May 13 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | S | 0.38 | 329,437 | 125,944 | 5,510,455 | 5.8 M to 5.5 M (-5.64 %) |
Apr 04 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | S | 0.41 | 147,664 | 60,542 | 5,839,892 | 6 M to 5.8 M (-2.47 %) |
Mar 31 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | S | 0.43 | 190,172 | 81,165 | 5,987,556 | 6.2 M to 6 M (-3.08 %) |
Mar 18 2014 | ELTP | ELITE PHARMACEUTIC ... | Ward Carter Julian | Chief Financial Off ... | Option Exercise | A | 0.12 | 150,000 | 18,000 | 150,000 | |
Mar 18 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Option Exercise | M | 0.06 | 180,000 | 10,800 | 0 | |
Mar 18 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Buy | M | 0.06 | 180,000 | 10,800 | 2,831,558 | 2.7 M to 2.8 M (+6.79 %) |
Mar 17 2014 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Sell | S | 0.60 | 239,367 | 144,003 | 20,300,770 | 20.5 M to 20.3 M (-1.17 %) |
Mar 17 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | S | 0.60 | 239,367 | 144,003 | 14,887,229 | 15.1 M to 14.9 M (-1.58 %) |
Mar 17 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Sell | S | 0.60 | 239,367 | 144,003 | 67,669,232 | 67.9 M to 67.7 M (-0.35 %) |
Mar 17 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Sell | S | 0.60 | 239,367 | 144,003 | 67,669,232 | 67.9 M to 67.7 M (-0.35 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | S | 0.68 | 1,051,450 | 714,986 | 14,939,890 | 16 M to 14.9 M (-6.58 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | NARINE JEENARINE | Director | Sell | S | 0.90 | 773,050 | 692,344 | 15,171,209 | 15.9 M to 15.2 M (-4.85 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Sell | S | 0.68 | 1,051,450 | 714,986 | 20,372,580 | 21.4 M to 20.4 M (-4.91 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | NIGALAYE ASHOK G | Chief Scientific Of ... | Sell | S | 0.90 | 773,050 | 692,344 | 20,688,015 | 21.5 M to 20.7 M (-3.60 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Sell | S | 0.68 | 1,051,450 | 714,986 | 67,908,599 | 69 M to 67.9 M (-1.52 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC PHARMA LLC | 10% Owner | Sell | S | 0.90 | 773,050 | 692,344 | 68,960,049 | 69.7 M to 69 M (-1.11 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Sell | S | 0.68 | 1,051,450 | 714,986 | 67,908,599 | 69 M to 67.9 M (-1.52 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Sell | S | 0.90 | 773,050 | 692,344 | 68,960,049 | 69.7 M to 69 M (-1.11 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Sell | S | 0.68 | 1,051,450 | 714,986 | 67,908,599 | 69 M to 67.9 M (-1.52 %) |
Mar 10 2014 | ELTP | ELITE PHARMACEUTIC ... | EPIC INVESTMENTS, LLC | 10% Owner | Sell | S | 0.90 | 773,050 | 692,344 | 68,960,049 | 69.7 M to 69 M (-1.11 %) |
Mar 03 2014 | ELTP | ELITE PHARMACEUTIC ... | TREPPEL JERRY | Chairman of the Boa ... | Grant | A | 0.09 | 330,159 | 30,011 | 2,760,006 | 2.4 M to 2.8 M (+13.59 %) |